Epic Sciences, Inc., a San Diego, CA-based diagnostics company, closed a $43m first close of its Series F financing.
The round was led by Arsenal Capital Partners, with participation from existing investors such as Blue Ox Healthcare Partners, Deerfield Management, and Labcorp. Concurrent with the financing round, Epic has also appointed two new members to its Board of Directors: James Rothman PhD, the Chair of Arsenal’s Healthcare Advisory Board, a renowned cell biologist and Nobel Laureate, who was formerly Chief Scientist of GE Healthcare, as well as Richard Eglen PhD, a Senior Advisor of Arsenal, who brings decades of industry leadership experience with companies such as PerkinElmer, Roche Bioscience, and Corning Inc.
The company will use the capital to continue to advance its multi-omic platform and expand operations in areas such as single-cell sequencing and data analytics infrastructure.
Led by Lloyd Sanders, President and CEO, Epic Sciences is developing and marketing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancers. The company’s liquid biopsy platform leverages proven, proprietary cell analysis capabilities as well as cell-free analysis to provide more complete, efficient analysis and clearer insights – Comprehensive Cancer Profiling. Using its full-service CAP/CLIA-accredited laboratory and research support services, the company partners with pharmaceutical companies and major cancer centers around the world to improve patient outcomes.
DefineMBC™, Epic’s novel blood-based test for comprehensively characterizing metastatic breast cancer, has been reporting patient results since April 2022. The test’s multi-analyte methods have demonstrated impressive sensitivity, specificity, accuracy, and precision in the:
- detection of circulating tumor cells (CTCs)
- assessment of protein expression (HER2, ER)
- determination of intra-cell copy number variations (CNV) within individual CTCs
- identification of single nucleotide variants (SNVs), indels, fusions, and CNVs from plasma-based cell-free DNA analysis, the calculation of microsatellite instability (MSI) and tumor mutational burden (TMB)
FinSMEs
02/06/2022